Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 107

1.

PAX8-GLIS3 gene fusion is a pathognomonic genetic alteration of hyalinizing trabecular tumors of the thyroid.

Marchiò C, Da Cruz Paula A, Gularte-Merida R, Basili T, Brandes A, da Silva EM, Silveira C, Ferrando L, Metovic J, Maletta F, Annaratone L, Pareja F, Rubin BP, Hoschar AP, De Rosa G, La Rosa S, Bongiovanni M, Purgina B, Piana S, Volante M, Weigelt B, Reis-Filho JS, Papotti M.

Mod Pathol. 2019 Jul 4. doi: 10.1038/s41379-019-0313-x. [Epub ahead of print]

PMID:
31273314
2.

ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research.

Marchiò C, Scaltriti M, Ladanyi M, Iafrate AJ, Bibeau F, Dietel M, Hechtman JF, Troiani T, López-Rios F, Douillard JY, Andrè F, Reis-Filho JS.

Ann Oncol. 2019 Jul 3. pii: mdz204. doi: 10.1093/annonc/mdz204. [Epub ahead of print]

PMID:
31268127
3.

Tissues under-vacuum to overcome suboptimal preservation.

Annaratone L, Marchiò C, Sapino A.

N Biotechnol. 2019 Sep 25;52:104-109. doi: 10.1016/j.nbt.2019.05.007. Epub 2019 May 28. Review.

4.

Neoplastic cell percentage estimation in tissue samples for molecular oncology: recommendations from a modified Delphi study.

Dufraing K, van Krieken JH, De Hertogh G, Hoefler G, Oniscu A, Kuhlmann TP, Weichert W, Marchiò C, Ristimäki A, Ryska A, Scoazec JY, Dequeker E.

Histopathology. 2019 May 4. doi: 10.1111/his.13891. [Epub ahead of print]

PMID:
31054167
5.

Assessment of a High Sensitivity Method for Identification of IDH1 R132x Mutations in Tumors and Plasma of Intrahepatic Cholangiocarcinoma Patients.

Peraldo-Neia C, Scatolini M, Grosso E, Lombardi P, Filippi R, Raggi C, Marchiò C, Cavalloni G, Aglietta M, Leone F.

Cancers (Basel). 2019 Mar 30;11(4). pii: E454. doi: 10.3390/cancers11040454.

6.

ESR1 mutations in metastatic lobular breast cancer patients.

Desmedt C, Pingitore J, Rothé F, Marchio C, Clatot F, Rouas G, Richard F, Bertucci F, Mariani O, Galant C, Fribbens C, O'Leary B, van den Eynden G, Salgado R, Turner NC, Piccart M, Vincent-Salomon A, Pruneri G, Larsimont D, Sotiriou C.

NPJ Breast Cancer. 2019 Feb 22;5:9. doi: 10.1038/s41523-019-0104-z. eCollection 2019.

7.

Thymidylate synthase maintains the de-differentiated state of triple negative breast cancers.

Siddiqui A, Gollavilli PN, Schwab A, Vazakidou ME, Ersan PG, Ramakrishnan M, Pluim D, Coggins S, Saatci O, Annaratone L, Hm Schellens J, Kim B, Asangani IA, Rasheed SAK, Marchiò C, Sahin O, Ceppi P.

Cell Death Differ. 2019 Feb 8. doi: 10.1038/s41418-019-0289-6. [Epub ahead of print]

8.

The Genomic Landscape of Mucinous Breast Cancer.

Pareja F, Lee JY, Brown DN, Piscuoglio S, Gularte-Mérida R, Selenica P, Da Cruz Paula A, Arunachalam S, Kumar R, Geyer FC, Silveira C, da Silva EM, Li A, Marchiò C, Ng CKY, Mariani O, Fuhrmann L, Wen HY, Norton L, Vincent-Salomon A, Brogi E, Reis-Filho JS, Weigelt B.

J Natl Cancer Inst. 2019 Jan 11. doi: 10.1093/jnci/djy216. [Epub ahead of print]

PMID:
30649385
9.

RollFISH achieves robust quantification of single-molecule RNA biomarkers in paraffin-embedded tumor tissue samples.

Wu C, Simonetti M, Rossell C, Mignardi M, Mirzazadeh R, Annaratone L, Marchiò C, Sapino A, Bienko M, Crosetto N, Nilsson M.

Commun Biol. 2018 Nov 28;1:209. doi: 10.1038/s42003-018-0218-0. eCollection 2018.

10.

CXCL12 expression is a bona fide predictor of recurrence in lung neuroendocrine tumours; a multicentric study with emphasis on atypical carcinoids - a short report.

Del Gobbo A, Fusco N, Barella M, Ercoli G, Sciarra A, Palleschi A, Pagni F, Marchiò C, Papotti M, Ferrero S.

Cell Oncol (Dordr). 2018 Dec;41(6):687-691. doi: 10.1007/s13402-018-0401-9. Epub 2018 Sep 4.

PMID:
30182340
11.

The expression of LINE1-MET chimeric transcript identifies a subgroup of aggressive breast cancers.

Miglio U, Berrino E, Panero M, Ferrero G, Coscujuela Tarrero L, Miano V, Dell'Aglio C, Sarotto I, Annaratone L, Marchiò C, Comoglio PM, De Bortoli M, Pasini B, Venesio T, Sapino A.

Int J Cancer. 2018 Dec 1;143(11):2838-2848. doi: 10.1002/ijc.31831. Epub 2018 Oct 4.

PMID:
30144023
12.

Medullary Breast Carcinoma, a Triple-Negative Breast Cancer Associated with BCLG Overexpression.

Romero P, Benhamo V, Deniziaut G, Fuhrmann L, Berger F, Manié E, Bhalshankar J, Vacher S, Laurent C, Marangoni E, Gruel N, MacGrogan G, Rouzier R, Delattre O, Popova T, Reyal F, Stern MH, Stoppa-Lyonnet D, Marchiò C, Bièche I, Vincent-Salomon A.

Am J Pathol. 2018 Oct;188(10):2378-2391. doi: 10.1016/j.ajpath.2018.06.021. Epub 2018 Aug 1.

PMID:
30075151
13.

The Dilemma of HER2 Double-equivocal Breast Carcinomas: Genomic Profiling and Implications for Treatment.

Marchiò C, Dell'Orto P, Annaratone L, Geyer FC, Venesio T, Berrino E, Verdun di Cantogno L, Garofoli A, Rangel N, Casorzo L, dell'Aglio C, Gugliotta P, Trisolini E, Beano A, Pietribiasi F, Orlassino R, Cassoni P, Pich A, Montemurro F, Mottolese M, Vincent-Salomon A, Penault-Llorca F, Medico E, Ng CKY, Viale G, Sapino A.

Am J Surg Pathol. 2018 Sep;42(9):1190-1200. doi: 10.1097/PAS.0000000000001100.

14.

Awareness of mutational artefacts in suboptimal DNA samples: possible risk for therapeutic choices.

Mariani S, Bertero L, Coppola V, Saracco G, Arezzo A, Francia Di Celle P, Metovic J, Marchiò C, Cassoni P.

Expert Rev Mol Diagn. 2018 May;18(5):467-475. doi: 10.1080/14737159.2018.1468254. Epub 2018 Apr 26.

PMID:
29676606
15.

High rate of PIK3CA mutations but no TP53 mutations in low-grade adenosquamous carcinoma of the breast.

Bataillon G, Fuhrmann L, Girard E, Menet E, Laé M, Capovilla M, Treilleux I, Arnould L, Penault-Llorca F, Rouzier R, Marchiò C, Bieche I, Vincent-Salomon A.

Histopathology. 2018 Aug;73(2):273-283. doi: 10.1111/his.13514. Epub 2018 May 7.

16.

Tumour Heterogeneity of Breast Cancer: From Morphology to Personalised Medicine.

Aleskandarany MA, Vandenberghe ME, Marchiò C, Ellis IO, Sapino A, Rakha EA.

Pathobiology. 2018;85(1-2):23-34. doi: 10.1159/000477851. Epub 2018 Feb 10. Review.

PMID:
29428954
17.

Molecular alterations of neuroendocrine tumours of the lung.

Rossi G, Bertero L, Marchiò C, Papotti M.

Histopathology. 2018 Jan;72(1):142-152. doi: 10.1111/his.13394. Review.

PMID:
29239031
18.

Classification of pulmonary neuroendocrine tumors: new insights.

Pelosi G, Sonzogni A, Harari S, Albini A, Bresaola E, Marchiò C, Massa F, Righi L, Gatti G, Papanikolaou N, Vijayvergia N, Calabrese F, Papotti M.

Transl Lung Cancer Res. 2017 Oct;6(5):513-529. doi: 10.21037/tlcr.2017.09.04. Review.

19.

Breast carcinomas with low amplified/equivocal HER2 by Ish: potential supporting role of multiplex ligation-dependent probe amplification.

Ercolani C, Marchiò C, Di Benedetto A, Fabi A, Perracchio L, Vici P, Sperati F, Buglioni S, Arena V, Pescarmona E, Sapino A, Terrenato I, Mottolese M.

J Exp Clin Cancer Res. 2017 Oct 13;36(1):143. doi: 10.1186/s13046-017-0613-2.

20.

Mitotic Spindle Assembly and Genomic Stability in Breast Cancer Require PI3K-C2α Scaffolding Function.

Gulluni F, Martini M, De Santis MC, Campa CC, Ghigo A, Margaria JP, Ciraolo E, Franco I, Ala U, Annaratone L, Disalvatore D, Bertalot G, Viale G, Noatynska A, Compagno M, Sigismund S, Montemurro F, Thelen M, Fan F, Meraldi P, Marchiò C, Pece S, Sapino A, Chiarle R, Di Fiore PP, Hirsch E.

Cancer Cell. 2017 Oct 9;32(4):444-459.e7. doi: 10.1016/j.ccell.2017.09.002.

21.

Comprehensive clinical and molecular analyses of neuroendocrine carcinomas of the breast.

Lavigne M, Menet E, Tille JC, Lae M, Fuhrmann L, Bonneau C, Deniziaut G, Melaabi S, Ng CCK, Marchiò C, Rouzier R, Bièche I, Vincent-Salomon A.

Mod Pathol. 2018 Jan;31(1):68-82. doi: 10.1038/modpathol.2017.107. Epub 2017 Sep 8.

22.

The impact of malignant nipple discharge cytology (NDc) in surgical management of breast cancer patients.

Castellano I, Metovic J, Balmativola D, Annaratone L, Rangel N, Vissio E, Arisio R, Macrì L, Pecchioni C, Sarotto I, Montarolo F, Muscarà F, Marchiò C, Cassoni P, Kulka J, Sapino A.

PLoS One. 2017 Aug 14;12(8):e0182073. doi: 10.1371/journal.pone.0182073. eCollection 2017.

23.

Acid-free glyoxal as a substitute of formalin for structural and molecular preservation in tissue samples.

Bussolati G, Annaratone L, Berrino E, Miglio U, Panero M, Cupo M, Gugliotta P, Venesio T, Sapino A, Marchiò C.

PLoS One. 2017 Aug 10;12(8):e0182965. doi: 10.1371/journal.pone.0182965. eCollection 2017.

24.

Next-generation learning and training: The Cy-TEST experience.

Fassina A, Cappellesso R, Tötsch M, Barroca H, Marchiò C, Dina R, Ovcin E, Bussolati G.

Cancer Cytopathol. 2017 Sep;125(9):669-673. doi: 10.1002/cncy.21895. Epub 2017 Jul 31. No abstract available.

25.

Triple-negative breast cancer: the importance of molecular and histologic subtyping, and recognition of low-grade variants.

Pareja F, Geyer FC, Marchiò C, Burke KA, Weigelt B, Reis-Filho JS.

NPJ Breast Cancer. 2016 Nov 16;2:16036. doi: 10.1038/npjbcancer.2016.36. eCollection 2016. Review.

26.

Massively parallel sequencing analysis of synchronous fibroepithelial lesions supports the concept of progression from fibroadenoma to phyllodes tumor.

Piscuoglio S, Geyer FC, Burke KA, Murray MP, Ng CK, Mota A, Marchio C, Berman SH, Norton L, Brogi E, Weigelt B, Reis-Filho JS.

NPJ Breast Cancer. 2016 Nov 16;2:16035. doi: 10.1038/npjbcancer.2016.35. eCollection 2016.

27.

Distinctive pathological and clinical features of lung carcinoids with high proliferation index.

Marchiò C, Gatti G, Massa F, Bertero L, Filosso P, Pelosi G, Cassoni P, Volante M, Papotti M.

Virchows Arch. 2017 Dec;471(6):713-720. doi: 10.1007/s00428-017-2177-0. Epub 2017 Jun 19.

28.

Extreme assay sensitivity in molecular diagnostics further unveils intratumour heterogeneity in metastatic colorectal cancer as well as artifactual low-frequency mutations in the KRAS gene.

Mariani S, Bertero L, Osella-Abate S, Di Bello C, Francia di Celle P, Coppola V, Sapino A, Cassoni P, Marchiò C.

Br J Cancer. 2017 Jul 25;117(3):358-366. doi: 10.1038/bjc.2017.170. Epub 2017 Jun 15.

29.

The expression of GHRH and its receptors in breast carcinomas with apocrine differentiation-further evidence of the presence of a GHRH pathway in these tumors.

Kővári B, Vranic S, Marchio C, Sapino A, Cserni G.

Hum Pathol. 2017 Jun;64:164-170. doi: 10.1016/j.humpath.2017.03.026. Epub 2017 Apr 21.

30.

Quantification of HER2 and estrogen receptor heterogeneity in breast cancer by single-molecule RNA fluorescence in situ hybridization.

Annaratone L, Simonetti M, Wernersson E, Marchiò C, Garnerone S, Scalzo MS, Bienko M, Chiarle R, Sapino A, Crosetto N.

Oncotarget. 2017 Mar 21;8(12):18680-18698. doi: 10.18632/oncotarget.15727.

31.

Genetic analysis of a morphologically heterogeneous ovarian endometrioid carcinoma.

Geyer FC, Pareja F, Burke KA, Schultheis AM, Hussein YR, Ye J, De Filippo MR, Marchio C, Macedo GS, Piscuoglio S, Lim RS, Toy E, Murali R, Jungbluth AA, Reis-Filho JS, Soslow RA, Weigelt B.

Histopathology. 2017 Sep;71(3):480-487. doi: 10.1111/his.13240. Epub 2017 Jun 16.

32.

Enhanced cytotoxic effect of camptothecin nanosponges in anaplastic thyroid cancer cells in vitro and in vivo on orthotopic xenograft tumors.

Gigliotti CL, Ferrara B, Occhipinti S, Boggio E, Barrera G, Pizzimenti S, Giovarelli M, Fantozzi R, Chiocchetti A, Argenziano M, Clemente N, Trotta F, Marchiò C, Annaratone L, Boldorini R, Dianzani U, Cavalli R, Dianzani C.

Drug Deliv. 2017 Nov;24(1):670-680. doi: 10.1080/10717544.2017.1303856.

33.

Genetic analysis of uterine adenosarcomas and phyllodes tumors of the breast.

Geyer FC, Burke KA, Piscuoglio S, Ng CKY, Papanastasiou AD, Marchiò C, Selenica P, Edelweiss M, Murray MP, Brogi E, Soslow RA, Rubin BP, Norton L, Reis-Filho JS, Weigelt B.

Mol Oncol. 2017 Aug;11(8):913-926. doi: 10.1002/1878-0261.12049. Epub 2017 May 16.

34.

Caveolin 1 expression favors tumor growth and is associated with poor survival in primary lung adenocarcinomas.

Duregon E, Senetta R, Bertero L, Bussolati B, Annaratone L, Pittaro A, Papotti M, Marchiò C, Cassoni P.

Tumour Biol. 2017 Feb;39(2):1010428317694311. doi: 10.1177/1010428317694311.

PMID:
28229621
35.

The genetic landscape of breast carcinomas with neuroendocrine differentiation.

Marchiò C, Geyer FC, Ng CK, Piscuoglio S, De Filippo MR, Cupo M, Schultheis AM, Lim RS, Burke KA, Guerini-Rocco E, Papotti M, Norton L, Sapino A, Weigelt B, Reis-Filho JS.

J Pathol. 2017 Feb;241(3):405-419. doi: 10.1002/path.4837. Epub 2016 Dec 26.

36.

Liquoral liquid biopsy in neoplastic meningitis enables molecular diagnosis and mutation tracking: a proof of concept.

Marchiò C, Mariani S, Bertero L, Di Bello C, Francia Di Celle P, Papotti M, Rudà R, Soffietti R, Cassoni P.

Neuro Oncol. 2017 Mar 1;19(3):451-453. doi: 10.1093/neuonc/now244. No abstract available.

37.

Genetic analysis of microglandular adenosis and acinic cell carcinomas of the breast provides evidence for the existence of a low-grade triple-negative breast neoplasia family.

Geyer FC, Berman SH, Marchiò C, Burke KA, Guerini-Rocco E, Piscuoglio S, Ng CK, Pareja F, Wen HY, Hodi Z, Schnitt SJ, Rakha EA, Ellis IO, Norton L, Weigelt B, Reis-Filho JS.

Mod Pathol. 2017 Jan;30(1):69-84. doi: 10.1038/modpathol.2016.161. Epub 2016 Oct 7.

38.

RNASeq analysis reveals biological processes governing the clinical behaviour of endometrioid and serous endometrial cancers.

Lemetre C, Vieites B, Ng CK, Piscuoglio S, Schultheis AM, Marchiò C, Murali R, Lopez-García MA, Palacios JC, Jungbluth AA, Terracciano LM, Reis-Filho JS, Weigelt B.

Eur J Cancer. 2016 Sep;64:149-58. doi: 10.1016/j.ejca.2016.05.028. Epub 2016 Jul 14.

39.

Effect of low doses of estradiol and tamoxifen on breast cancer cell karyotypes.

Rondón-Lagos M, Rangel N, Di Cantogno LV, Annaratone L, Castellano I, Russo R, Manetta T, Marchiò C, Sapino A.

Endocr Relat Cancer. 2016 Aug;23(8):635-50. doi: 10.1530/ERC-16-0078. Epub 2016 Jun 29.

40.

BCAM and LAMA5 Mediate the Recognition between Tumor Cells and the Endothelium in the Metastatic Spreading of KRAS-Mutant Colorectal Cancer.

Bartolini A, Cardaci S, Lamba S, Oddo D, Marchiò C, Cassoni P, Amoreo CA, Corti G, Testori A, Bussolino F, Pasqualini R, Arap W, Corà D, Di Nicolantonio F, Marchiò S.

Clin Cancer Res. 2016 Oct 1;22(19):4923-4933. Epub 2016 May 3.

41.

Rediscovering Secondary Tumors of the Prostate in the Molecular Era.

Fusco N, Sciarra A, Guerini-Rocco E, Marchiò C, Vignani F, Colombo P, Ferrero S.

Adv Anat Pathol. 2016 May;23(3):170-9. doi: 10.1097/PAP.0000000000000115. Review.

PMID:
27058245
42.

Massively parallel sequencing of phyllodes tumours of the breast reveals actionable mutations, and TERT promoter hotspot mutations and TERT gene amplification as likely drivers of progression.

Piscuoglio S, Ng CK, Murray M, Burke KA, Edelweiss M, Geyer FC, Macedo GS, Inagaki A, Papanastasiou AD, Martelotto LG, Marchio C, Lim RS, Ioris RA, Nahar PK, Bruijn ID, Smyth L, Akram M, Ross D, Petrini JH, Norton L, Solit DB, Baselga J, Brogi E, Ladanyi M, Weigelt B, Reis-Filho JS.

J Pathol. 2016 Mar;238(4):508-18. doi: 10.1002/path.4672. Epub 2016 Jan 25.

43.

"Giants in a Microcosm": Multinucleated Giant Cells Populating an Invasive Micropapillary Carcinoma of the Breast.

Marchiò C, Pietribiasi F, Castiglione R, Fusco N, Sapino A.

Int J Surg Pathol. 2015 Dec;23(8):654-5. doi: 10.1177/1066896915605616. Epub 2015 Sep 13. No abstract available.

44.

Monosomy of chromosome 17 in breast cancer during interpretation of HER2 gene amplification.

Brunelli M, Nottegar A, Bogina G, Caliò A, Cima L, Eccher A, Vicentini C, Marcolini L, Scarpa A, Pedron S, Brunello E, Knuutila S, Sapino A, Marchiò C, Bria E, Molino A, Carbognin L, Tortora G, Jasani B, Miller K, Merdol I, Zanatta L, Laurino L, Wirtanen T, Zamboni G, Marconi M, Chilosi M, Manfrin E, Martignoni G, Bonetti F.

Am J Cancer Res. 2015 Jun 15;5(7):2212-21. eCollection 2015.

45.

Immunohistochemical and molecular profiling of histologically defined apocrine carcinomas of the breast.

Vranic S, Marchiò C, Castellano I, Botta C, Scalzo MS, Bender RP, Payan-Gomez C, di Cantogno LV, Gugliotta P, Tondat F, di Celle PF, Mariani S, Gatalica Z, Sapino A.

Hum Pathol. 2015 Sep;46(9):1350-9. doi: 10.1016/j.humpath.2015.05.017. Epub 2015 Jun 5.

PMID:
26208846
46.

The Perfect Pathology Report After Neoadjuvant Therapy.

Marchiò C, Maletta F, Annaratone L, Sapino A.

J Natl Cancer Inst Monogr. 2015 May;2015(51):47-50. doi: 10.1093/jncimonographs/lgv016.

PMID:
26063886
47.

The repertoire of somatic genetic alterations of acinic cell carcinomas of the breast: an exploratory, hypothesis-generating study.

Guerini-Rocco E, Hodi Z, Piscuoglio S, Ng CK, Rakha EA, Schultheis AM, Marchiò C, da Cruz Paula A, De Filippo MR, Martelotto LG, De Mattos-Arruda L, Edelweiss M, Jungbluth AA, Fusco N, Norton L, Weigelt B, Ellis IO, Reis-Filho JS.

J Pathol. 2015 Oct;237(2):166-78. doi: 10.1002/path.4566. Epub 2015 Jul 29.

48.

MED12 somatic mutations in fibroadenomas and phyllodes tumours of the breast.

Piscuoglio S, Murray M, Fusco N, Marchiò C, Loo FL, Martelotto LG, Schultheis AM, Akram M, Weigelt B, Brogi E, Reis-Filho JS.

Histopathology. 2015 Nov;67(5):719-29. doi: 10.1111/his.12712. Epub 2015 May 24.

49.

Critical roles of specimen type and temperature before and during fixation in the detection of phosphoproteins in breast cancer tissues.

Gündisch S, Annaratone L, Beese C, Drecol E, Marchiò C, Quaglino E, Sapino A, Becker KF, Bussolati G.

Lab Invest. 2015 May;95(5):561-71. doi: 10.1038/labinvest.2015.37. Epub 2015 Mar 2.

50.

PIKing the type and pattern of PI3K pathway mutations in endometrioid endometrial carcinomas.

Marchiò C, De Filippo MR, Ng CK, Piscuoglio S, Soslow RA, Reis-Filho JS, Weigelt B.

Gynecol Oncol. 2015 May;137(2):321-8. doi: 10.1016/j.ygyno.2015.02.010. Epub 2015 Feb 18.

PMID:
25701704

Supplemental Content

Loading ...
Support Center